secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001654954-24-011213
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences gets Nasdaq extension to Nov 20, 2024 to regain $1 bid price; 91% of Series B warrants exercised
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted extension until November 20, 2024 to regain compliance with $1.00 minimum bid price for 10 consecutive trading days.
- Company is evaluating options to evidence compliance; no immediate effect on listing or trading of NDRA common stock.
- 91% of Series B warrants from June 2024 public offering exercised, resulting in issuance of 15,831,864 shares of common stock.
- Total outstanding common shares increased to 17,280,655 as of August 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424011213/0001654954-24-011213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424011213/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-011213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer